irblog.prnewswire.com

FDA Approval of BELBUCA™ (CIII) (Buprenorphine HCl) Buccal Film for Chronic Pain Triggers Milestone Payment of $50 Million to BioDelivery Sciences from Partner Endo ...

RALEIGH, N.C., Oct. 26, 2015 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) and its partner Endo Pharmaceuticals Inc. (Endo), a subsidiary of Endo International plc (NASDAQ: ...
irblog.prnewswire.com

BioDelivery Sciences Presents Data on BELBUCA® (buprenorphine) Buccal Film at the PAINWeek 2017 Conference

RALEIGH, N.C., Sept. 7, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) presented three posters including results from an analysis of data which evaluated the reported ...
Yahoo Finance

BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS) Meeting

RALEIGH, N.C., Jan. 15, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic ...
News Medical

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

New treatment option combines proven efficacy and established safety profile of buprenorphine with a novel delivery system that adds convenience and flexibility Endo Pharmaceuticals Inc., a subsidiary ...
Yahoo Finance

BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAINWeek 2021 Conference

"These posters include important scientific data for healthcare professionals to consider concerning the safety profile of buprenorphine buccal film and oxycodone," said Thomas Smith, MD, Chief ...
Nasdaq

BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine’s 36th Annual Meeting

--BioDelivery Sciences International, Inc., a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today presented at the American ...
FiercePharma

Endo Announces Launch Of BELBUCA™ (Buprenorphine) Buccal Film For Chronic Pain Management

DUBLIN , Feb. 22, 2016 /CNW/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (ENDP) (ENL.TO), today announced the availability of BELBUCA™ (buprenorphine) buccal film, the first ...
FierceBiotech

U.S. FDA Approves BELBUCA™ (buprenorphine) Buccal Film for Chronic Pain Management

New treatment option combines proven efficacy and established safety profile of buprenorphine with a novel delivery system that adds convenience and flexibility ...
Business Insider

BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS) Meeting

Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory Outcomes Comparing BELBUCA ® to Oxycodone on January 16 from 1:10pm – 2:10pm CT RALEIGH, N.C., Jan. 15, 2021 (GLOBE NEWSWIRE ...
Finanznachrichten

Endo Announces Launch Of BELBUCA' (Buprenorphine) Buccal Film For Chronic Pain Management

BELBUCA' (buprenorphine) buccal film is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options ...
PR Newswire

Endo Announces Launch Of BELBUCA™ (Buprenorphine) Buccal Film For Chronic Pain Management

New opioid analgesic with novel drug delivery now available by prescription in U.S. DUBLIN, Feb. 22, 2016 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ...